HIV/AIDS Research Report

  1. Palella, F.J., Jr., et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med, 1998. 338(13): p. 853-60.
  2. Greenwald, J.L., et al., A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep, 2006. 8(2): p. 125-31.
  3. King, K.M., et al., Co-occurrence of Sexual Risk Behaviors and Substance Use Across Emerging Adulthood: Evidence for State- and Trait-level Associations. Addiction, 2012.
  4. The NSDUH Report: HIV/AIDS and Substance Use, 2010, Substance Abuse and Mental Health Services Administration: Rockville, MD.
  5. Marcondes, M.C., et al., Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys. Am J Pathol, 2010. 177(1): p. 355-61.
  6. Langford, D., et al., Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr, 2003. 34(5): p. 467-74.
  7. Rippeth, J.D., et al., Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc, 2004. 10(1): p. 1-14.
  8. Cohen, S.M., et al., Vital Signs: HIV Prevention Through Care and Treatment - United States, in Morbidity and Mortality Weekly Report 2011, Centers for Disease Control and Prevention. p. 1618-1623.
  9. Degenhardt, L., et al., Meth/ amphetamine use and associated HIV: Implications for global policy and public health. Int J Drug Policy, 2010. 21(5): p. 347-58.
  10. Phair, J. and F. Palella, Renal disease in HIV-infected individuals. Curr Opin HIV AIDS, 2011. 6(4): p. 285-9.
  11. Mallon, P.W., HIV and bone mineral density. Curr Opin Infect Dis, 2010. 23(1): p. 1-8.
  12. Falade-Nwulia, O. and C.L. Thio, Liver disease, HIV and aging. Sex Health, 2011. 8(4): p. 512-20.
  13. Dukers, N.H., et al., Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS, 2001. 15(3): p. 369-78.
  14. Vanable, P.A., et al., Impact of combination therapies on HIV risk perceptions and sexual risk among HIV-positive and HIV-negative gay and bisexual men. Health Psychol, 2000. 19(2): p. 134-45.
  15. Boily, M.C., et al., Changes in the transmission dynamics of the HIV epidemic after the wide-scale use of antiretroviral therapy could explain increases in sexually transmitted infections: results from mathematical models. Sex Transm Dis, 2004. 31(2): p. 100-13.
  16. Tun, W., et al., Attitudes toward HIV treatments influence unsafe sexual and injection practices among injecting drug users. AIDS, 2003. 17(13): p. 1953-62.
  17. Rahmanian, S., et al., Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc, 2011. 8(3): p. 313-9.
  18. Wejnert, C., et al., HIV Infection and HIVAssociated Behaviors Among Injecting Drug Users - 20 Cities, United States, 2009, in Morbidity and Mortality Weekly Report 2012, Centers for Disease Control and Prevention. p. 133-138.
  19. Stone, V.E., HIV/AIDS in Women and Racial/ Ethnic Minorities in the U.S. Curr Infect Dis Rep, 2012. 14(1): p. 53-60.
  20. Intersecting Risks:HIV Infection Among Heterosexual Women and Men in Massachusetts, 2010, Bureau of Infectious Disease, Office of HIV/AIDS.
  21. Machtinger, E.L., et al., Psychological Trauma and PTSD in HIV-Positive Women: A Meta-Analysis. AIDS Behav, 2012.
  22. Armstrong, G.L., et al., The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med, 2006. 144(10): p. 705-14.
  23. Ghany, M.G., et al., An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 2011. 54(4): p. 1433-44.
  24. Hallfors, D.D., et al., Sexual and drug behavior patterns and HIV and STD racial disparities: the need for new directions. Am J Public Health, 2007. 97(1): p. 125-32.
  25. Currier, J., et al., Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med, 2010. 153(6): p. 349-57.
  26. Althoff, K.N., et al., CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther, 2010. 7: p. 45.
  27. Smith, G., HIV Over Fifty: Exploring the New Threat, in Special Committee on Aging, U.S. Senate 2005, U.S. Government Printing Office: Washington, D.C. p. 1.
  28. Doyle, K., et al., Aging, Prospective Memory, and Health-Related Quality of Life in HIV Infection. AIDS Behav, 2012.
  29. Maruschak, L.M., Bureau of Justice Statistics: HIV in Prisons, 2007-2008, 2010, U.S. Department of Justice.
  30. Spaulding, A.C., et al., HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS One, 2009. 4(11): p. e7558.
  31. Mumola, C.J. and J.C. Karber, Special Report: Drug Use and Dependence, State and Federal Prisoners, 2004, 2007, U.S. Department of Justice.
  32. Beckwith, C.G., et al., Opportunities to diagnose, treat, and prevent HIV in the criminal justice system. J Acquir Immune Defic Syndr, 2010. 55 Suppl 1: p. S49-55.
  33. Metzger, D.S., H. Navaline, and G.E. Woody, Drug abuse treatment as AIDS prevention. Public Health Rep, 1998. 113 Suppl 1: p. 97-106.
  34. Schroeder, J.R., et al., Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addict Behav, 2006. 31(5): p. 868-79.
  35. Westergaard, R.P., et al., Provider and cliniclevel correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers. J Int AIDS Soc, 2012. 15: p. 10.
  36. Wood, E., et al., Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA, 2008. 300(5): p. 550-4.
  37. Roux, P., et al., The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction, 2008. 103(11): p. 1828-36.
  38. Korthuis, P.T., et al., Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr, 2011. 56 Suppl 1: p. S83-90.
  39. McCance-Katz, E.F., Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis, 2005. 41 Suppl 1: p. S89-95.
  40. McCance-Katz, E.F. and T.W. Mandell, Drug interactions of clinical importance with methadone and buprenorphine. Am J Addict, 2010. 19(1): p. 2-3.
  41. Carrieri, M.P., et al., Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. Drug Alcohol Depend, 2000. 60(1): p. 51-4.
  42. Sanders, G.D., et al., Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med, 2005. 352(6): p. 570-85.
  43. Cohen, M.S., et al., Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med, 2011. 365(6): p. 493-505.
  44. Montaner, J.S., et al., Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet, 2010. 376(9740): p. 532-9.
  45. Kirk, G., et al., Decline in Community Viral Load Strongly Associated with Declining HIV Incidence among IDU, in 18th Conference on Retroviruses and Opportunistic Infections 2011: Boston, MA.